FGF-23 and cardiovascular disease: review of literature

Jasveen Batra, Rupinder Singh Buttar, Pardeep Kaur, Jacqueline Kreimerman, Michal L. Melamed

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: This review examines associations between fibroblast growth factor 23 (FGF-23) and cardiovascular disease. RECENT FINDINGS: FGF-23 is a hormone produced by osteocytes and osteoblasts that aids with phosphate excretion by the kidney and acts as a negative feedback regulator for activated vitamin D synthesis. Recent studies have found associations between elevated FGF-23 levels and a number of cardiovascular diseases, including hypertension, left ventricular hypertrophy, endothelial dysfunction, cardiovascular events and mortality. CONCLUSION: Recent studies have explored the possible effects of FGF-23 on the cardiovascular system. In animal and observational human studies, there is a link between elevated FGF-23 levels and multiple cardiovascular outcomes, including hypertension, left ventricular hypertrophy and cardiovascular events and mortality. Further studies are required to evaluate whether decreasing FGF-23 levels improves cardiovascular outcomes.

Original languageEnglish (US)
JournalCurrent Opinion in Endocrinology, Diabetes and Obesity
DOIs
StateAccepted/In press - Sep 20 2016

Fingerprint

Cardiovascular Diseases
Left Ventricular Hypertrophy
Hypertension
Osteocytes
Mortality
Cardiovascular System
Osteoblasts
Vitamin D
Observational Studies
fibroblast growth factor 23
Phosphates
Hormones
Kidney

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Nutrition and Dietetics

Cite this

FGF-23 and cardiovascular disease : review of literature. / Batra, Jasveen; Buttar, Rupinder Singh; Kaur, Pardeep; Kreimerman, Jacqueline; Melamed, Michal L.

In: Current Opinion in Endocrinology, Diabetes and Obesity, 20.09.2016.

Research output: Contribution to journalArticle

Batra, Jasveen ; Buttar, Rupinder Singh ; Kaur, Pardeep ; Kreimerman, Jacqueline ; Melamed, Michal L. / FGF-23 and cardiovascular disease : review of literature. In: Current Opinion in Endocrinology, Diabetes and Obesity. 2016.
@article{992975ffab7e459c90701ac451b8a272,
title = "FGF-23 and cardiovascular disease: review of literature",
abstract = "PURPOSE OF REVIEW: This review examines associations between fibroblast growth factor 23 (FGF-23) and cardiovascular disease. RECENT FINDINGS: FGF-23 is a hormone produced by osteocytes and osteoblasts that aids with phosphate excretion by the kidney and acts as a negative feedback regulator for activated vitamin D synthesis. Recent studies have found associations between elevated FGF-23 levels and a number of cardiovascular diseases, including hypertension, left ventricular hypertrophy, endothelial dysfunction, cardiovascular events and mortality. CONCLUSION: Recent studies have explored the possible effects of FGF-23 on the cardiovascular system. In animal and observational human studies, there is a link between elevated FGF-23 levels and multiple cardiovascular outcomes, including hypertension, left ventricular hypertrophy and cardiovascular events and mortality. Further studies are required to evaluate whether decreasing FGF-23 levels improves cardiovascular outcomes.",
author = "Jasveen Batra and Buttar, {Rupinder Singh} and Pardeep Kaur and Jacqueline Kreimerman and Melamed, {Michal L.}",
year = "2016",
month = "9",
day = "20",
doi = "10.1097/MED.0000000000000294",
language = "English (US)",
journal = "Current Opinion in Endocrinology, Diabetes and Obesity",
issn = "1752-296X",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - FGF-23 and cardiovascular disease

T2 - review of literature

AU - Batra, Jasveen

AU - Buttar, Rupinder Singh

AU - Kaur, Pardeep

AU - Kreimerman, Jacqueline

AU - Melamed, Michal L.

PY - 2016/9/20

Y1 - 2016/9/20

N2 - PURPOSE OF REVIEW: This review examines associations between fibroblast growth factor 23 (FGF-23) and cardiovascular disease. RECENT FINDINGS: FGF-23 is a hormone produced by osteocytes and osteoblasts that aids with phosphate excretion by the kidney and acts as a negative feedback regulator for activated vitamin D synthesis. Recent studies have found associations between elevated FGF-23 levels and a number of cardiovascular diseases, including hypertension, left ventricular hypertrophy, endothelial dysfunction, cardiovascular events and mortality. CONCLUSION: Recent studies have explored the possible effects of FGF-23 on the cardiovascular system. In animal and observational human studies, there is a link between elevated FGF-23 levels and multiple cardiovascular outcomes, including hypertension, left ventricular hypertrophy and cardiovascular events and mortality. Further studies are required to evaluate whether decreasing FGF-23 levels improves cardiovascular outcomes.

AB - PURPOSE OF REVIEW: This review examines associations between fibroblast growth factor 23 (FGF-23) and cardiovascular disease. RECENT FINDINGS: FGF-23 is a hormone produced by osteocytes and osteoblasts that aids with phosphate excretion by the kidney and acts as a negative feedback regulator for activated vitamin D synthesis. Recent studies have found associations between elevated FGF-23 levels and a number of cardiovascular diseases, including hypertension, left ventricular hypertrophy, endothelial dysfunction, cardiovascular events and mortality. CONCLUSION: Recent studies have explored the possible effects of FGF-23 on the cardiovascular system. In animal and observational human studies, there is a link between elevated FGF-23 levels and multiple cardiovascular outcomes, including hypertension, left ventricular hypertrophy and cardiovascular events and mortality. Further studies are required to evaluate whether decreasing FGF-23 levels improves cardiovascular outcomes.

UR - http://www.scopus.com/inward/record.url?scp=84988578969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988578969&partnerID=8YFLogxK

U2 - 10.1097/MED.0000000000000294

DO - 10.1097/MED.0000000000000294

M3 - Article

C2 - 27652999

AN - SCOPUS:84988578969

JO - Current Opinion in Endocrinology, Diabetes and Obesity

JF - Current Opinion in Endocrinology, Diabetes and Obesity

SN - 1752-296X

ER -